Stock PSNL PERSONALIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Personalis, Inc.

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:16:44 2024-04-19 am EDT 		5-day change 1st Jan Change
1.255 USD +3.72% Intraday chart for Personalis, Inc. -1.18% -40.00%
Mar. 26 Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring CI
Feb. 29 Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating MT

Business Summary

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Number of employees: 224

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharma Tests and Services
43.4 %
30 45.4 % 32 43.4 % +7.96%
Enterprise
43.2 %
27 41.0 % 32 43.2 % +19.10%
Population Sequencing
12.8 %
8 13.0 % 9 12.8 % +11.48%
Other
0.6 %
0 0.6 % 0 0.6 % +6.08%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
90.0 %
59 91.0 % 66 90.0 % +11.72%
International
10.0 %
6 9.0 % 7 10.0 % +25.52%

Managers

Managers TitleAgeSince
Christopher Hall CEO
 Chief Executive Officer 55 22-10-30
Aaron Tachibana DFI
 Director of Finance/CFO 63 19-02-28
Richard Chen CTO
 Chief Tech/Sci/R&D Officer 53 11-10-31
Caroline Corner IRC
 Investor Relations Contact - -
Deepshikha Bhandari LAW
 General Counsel - 23-10-17
James Azzaro SAM
 Sales & Marketing - 22-04-20
Stephane Mouradian SAM
 Sales & Marketing - -
John Lyle PRN
 Corporate Officer/Principal - 20-07-15
Susan Moriconi HRO
 Human Resources Officer - 20-12-31
Christian D. Haudenschild PRN
 Corporate Officer/Principal - 11-12-31

Members of the board

Members of the board TitleAgeSince
Arthur Blaine Bowman BRD
 Director/Board Member 77 19-04-30
Kenneth Widder BRD
 Director/Board Member 71 23-06-13
Woodrow Myers BRD
 Director/Board Member 70 21-03-05
Christopher Hall CEO
 Chief Executive Officer 55 22-10-30
Lonnie Shoff BRD
 Director/Board Member 65 22-07-31
Karin Eastham CHM
 Chairman 74 19-09-08
Olivia Bloom BRD
 Director/Board Member 55 22-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,209,828 50,791,176 ( 99.18 %) 0 99.18 %

Shareholders

NameEquities%Valuation
Lightspeed Management Co LLC
16.17 %
8,165,484 16.17 % 12 M $
ARK Investment Management LLC
13.21 %
6,671,545 13.21 % 10 M $
BlackRock Advisors LLC
6.377 %
3,220,436 6.377 % 5 M $
Vanguard Global Advisers LLC
4.099 %
2,070,094 4.099 % 3 M $
Nikko Asset Management Americas, Inc.
2.146 %
1,083,685 2.146 % 2 M $
Renaissance Technologies LLC
1.665 %
840,811 1.665 % 1 M $
John S. West
1.232 %
622,444 1.232 % 927 442 $
Acadian Asset Management LLC
1.030 %
520,182 1.030 % 775 071 $
Wellington Shields Capital Management LLC
0.9461 %
477,831 0.9461 % 711 968 $
D.E. Shaw & Co., Inc.
0.9212 %
465,242 0.9212 % 693 211 $

Company contact information

Personalis, Inc.

6600 Dumbarton Circle

94555, Fremont

+650 752 1300

http://www.personalis.com
address Personalis, Inc.(PSNL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Personalis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.21 USD
Average target price
4.75 USD
Spread / Average Target
+292.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PERSONALIS, INC. Stock Personalis, Inc.
-42.38% 61.96M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.89% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PSNL Stock
  4. Company Personalis, Inc.